We evaluated OSI-774, a novel EGFR tyrosine kinase inhibitor (TKI) in MPM and correlated tumor molecular expression of the EGFR s ... (TKI) in MPM and correlated tumor molecular expression of the EGFR ...

AstraZeneca (AZ) has shared positive overall survival (OS) results from a late-stage study of its epidermal growth factor ...

The non-transmembrane protein tyrosine phosphatase SHP2 plays an essential role in most, if not all, RTK signaling pathways activating ERK and downregulating BIM. Patients with low BIM and high SHP2 ...

A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...

Suzhou Puhe Biopharma Co. Ltd. presented promising preclinical profile data on PH009-1, a novel fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Besides ...

Blueprint Medicines is pulling back from one of its three areas of focus, dropping two non-small cell lung cancer (NSCLC) programs in response to early clinical data on the EGFR tyrosine kinase ...

A new research paper was published in Aging's Volume 15, Issue 13, entitled, “Budding uninhibited by benzimidazoles-1 (BUB1) regulates EGFR signaling by reducing EGFR internalization.” ...

Daiichi Sankyo and Merck have voluntarily withdrawn the Biologics License Application (BLA) for patritumab deruxtecan, an investigational human epidermal growth factor receptor 3 (HER3)-directed ...

Investor Enquiries +852 2121 8200 / ir@hutch-med.com Media Enquiries FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com Ben Atwell / Alex Shaw +44 7771 913 902 (Mobile) / +44 7779 ...